BeOne Medicines Ltd.SSE: 688235

Announcement on Renewing Engagement of Audit Institution for 2025

Mar 25, 2025 · Issued by BeOne Medicines Ltd. via Shanghai Stock Exchange

Filed with SSE · Mar 25, 2025

On 6ix: 6ix.com/news/announcement-on-renewing-engagement-of-audit-institution-for-2025-19

Announcement on Renewing Engagement of Audit Institution for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

BeOne Medicines Ltd. on 6ix

Earlier from BeOne Medicines

Announcement on the Equity Registration Date for the 1st Extraordinary General Meeting in 2025Mar 12, 2025
Notice on Convening the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2025Mar 11, 2025
Indicative Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1%Mar 7, 2025
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with ChemotherapyMar 4, 2025
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesFeb 27, 2025

Later from BeOne Medicines

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung CancerMar 31, 2025
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development ProgramApr 3, 2025
Notice on Convening the 2025 Annual General MeetingApr 8, 2025
BeiGene to Announce First Quarter 2025 Financial Results on May 7Apr 17, 2025
Announcement on Convening the 2024 Annual Performance BriefingApr 19, 2025

All BeOne Medicines news releases

Follow BeOne Medicines into a list and get an email when it puts out news.

Follow BeOne Medicines